DDInter1054 DDInter1376
Levodopa is a prodrug of dopamine that is administered to patients with Parkinson's due to its ability to cross the blood-brain barrier[Label]. Levodopa can be metabolised to dopamine on either side of the blood-brain barrier and so it is generally administered with a dopa decarboxylase inhibitor like carbidopa to prevent metabolism until after it has crossed the blood-brain barrier[Label,A177781]. Once past the blood-brain barrier, levodopa is metabolized to dopamine and supplements the low endogenous levels of dopamine to treat symptoms of Parkinson's[Label]. The first developed drug product that was approved by the FDA was a levodopa and carbidopa combined product called Sinemet that was approved on May 2, 1975[A177781,L6133].
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Levodopa {u} (Compound) resembles {v} (Compound) Levonordefrin
Levodopa {u} (Compound) resembles {v} (Compound) Isoetharine
Levodopa {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Epinephrine
Levodopa {u} (Compound) binds {v} (Gene) DRD1
Levodopa {u} (Compound) upregulates {v} (Gene) CADM1
Levodopa {u} (Compound) palliates {v} (Disease) restless legs syndrome
Levodopa {u} (Compound) is included by {v} (Pharmacologic Class) DOPA Decarboxylase Inhibitors
Levodopa {u} (Compound) downregulates {v} (Gene) P4HTM
Levodopa {u} (Compound) causes {v} (Side Effect) Hyperhidrosis
Levodopa {u} may cause a minor interaction that can limit clinical effects when taken with {v} Aluminum hydroxide
Levodopa (Compound) resembles Levonordefrin (Compound)
Levodopa (Compound) resembles Isoetharine (Compound)
Levodopa may cause a moderate interaction that could exacerbate diseases when taken with Epinephrine
Levodopa (Compound) binds DRD1 (Gene)
Levodopa (Compound) upregulates CADM1 (Gene)
Levodopa (Compound) palliates restless legs syndrome (Disease)
Levodopa (Compound) is included by DOPA Decarboxylase Inhibitors (Pharmacologic Class)
Levodopa (Compound) downregulates P4HTM (Gene)
Levodopa (Compound) causes Hyperhidrosis (Side Effect)
Levodopa may cause a minor interaction that can limit clinical effects when taken with Aluminum hydroxide